Pacira CMO granted 54,546 restricted stock units

SLONIN JONATHAN reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

SLONIN JONATHAN reported acquisition or exercise transactions in this Form 4 filing.

Pacira BioSciences, Inc. reported that Chief Medical Officer Jonathan Slonin received an equity award of 54,546 shares of common stock on February 11, 2026. The award was granted at a price of $0 per share and is structured as restricted stock units.

These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as Slonin remains in continuous service with the company on each vesting date. After this grant, he beneficially owns 226,901.175 shares of Pacira common stock directly.

Insider Trade Summary

Grant/Award: 54,546 shares

Grant/Award 1 txn

Insider SLONIN JONATHAN

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	54,546	$0.00	$0.00

Holdings After Transaction: Common Stock — 226,901.175 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pacira BioSciences (PCRX) report for Jonathan Slonin?

Pacira BioSciences reported that Chief Medical Officer Jonathan Slonin received a grant of 54,546 restricted stock units of common stock on February 11, 2026. The award was recorded at $0 per share and increased his directly held beneficial ownership to 226,901.175 shares.

How do the new Pacira (PCRX) restricted stock units for Jonathan Slonin vest?

The 54,546 restricted stock units granted to Jonathan Slonin vest in four equal annual installments starting on February 15, 2027. Each installment requires that he remain in continuous service with Pacira BioSciences through the applicable vesting date to receive the underlying common shares.

Is the Pacira (PCRX) Form 4 transaction a stock purchase or an equity award?

The Form 4 transaction for Pacira’s Chief Medical Officer is an equity award, not an open-market stock purchase. It is coded as an acquisition (grant or award) of 54,546 restricted stock units at $0 per share, reflecting compensation rather than a cash investment in shares.

What is Jonathan Slonin’s Pacira (PCRX) share ownership after the latest grant?

Following the February 11, 2026 award, Jonathan Slonin beneficially owns 226,901.175 shares of Pacira common stock directly. This total includes the newly granted 54,546 restricted stock units, each representing a contingent right to receive one share upon vesting conditions being satisfied.

What conditions apply to the Pacira (PCRX) restricted stock units granted to Jonathan Slonin?

Each restricted stock unit represents the contingent right to receive one Pacira common share, subject to vesting. The units vest in four equal annual installments starting February 15, 2027, and require that Jonathan Slonin remain in continuous service with the company on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SLONIN JONATHAN

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		A		54,546(1)	A	$0	226,901.175	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.